UK Glp-1 Receptor Agonist Market Size & Outlook, 2024-2030
UK glp-1 receptor agonist market, 2018-2030 (US$M)
Related Markets
UK glp-1 receptor agonist market highlights
- The UK glp-1 receptor agonist market generated a revenue of USD 566.3 million in 2023 and is expected to reach USD 2,672.3 million by 2030.
- The UK market is expected to grow at a CAGR of 24.8% from 2024 to 2030.
- In terms of segment, ozempic (semaglutide) was the largest revenue generating product in 2023.
- Other Products is the most lucrative product segment registering the fastest growth during the forecast period.
Glp-1 receptor agonist market data book summary
| Market revenue in 2023 | USD 566.3 million |
| Market revenue in 2030 | USD 2,672.3 million |
| Growth rate | 24.8% (CAGR from 2023 to 2030) |
| Largest segment | Ozempic (semaglutide) |
| Fastest growing segment | Other Products |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Ozempic (semaglutide), Trulicity, Rybelsus (oral semaglutide), Saxenda, Other Products |
Other key industry trends
- In terms of revenue, UK accounted for 1.5% of the global glp-1 receptor agonist market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Europe, Germany glp-1 receptor agonist market is projected to lead the regional market in terms of revenue in 2030.
- Norway is the fastest growing regional market in Europe and is projected to reach USD 1,225.8 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
GLP-1 Receptor Agonist Market Scope
GLP-1 Receptor Agonist Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
UK glp-1 receptor agonist market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to glp-1 receptor agonist market will help companies and investors design strategic landscapes.
Ozempic (semaglutide) was the largest segment with a revenue share of 44.78% in 2024. Horizon Databook has segmented the UK glp-1 receptor agonist market based on ozempic (semaglutide), trulicity, rybelsus (oral semaglutide), saxenda, other products covering the revenue growth of each sub-segment from 2018 to 2030.
The GLP-1 receptor agonist market in the UK is one of the major markets in the region. Regional players are engaged in developing effective & economical therapeutics to address the increasing prevalence and growing need for therapeutics, fueling market growth in the country.
For instance, according to the British Diabetic Association, Diabetes UK, more than 5.6 million people in the UK are living with diabetes. Furthermore, major players are investing in pharmaceutical R&D to develop novel therapeutics, driving market growth in the country.
Favorable government initiatives and increased R&D activities in the country are also propelling the market. In addition, the high disease burden and significant government initiatives to spread awareness of various target diseases contribute to market growth.
Reasons to subscribe to UK glp-1 receptor agonist market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of UK glp-1 receptor agonist market databook
-
Our clientele includes a mix of glp-1 receptor agonist market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the UK glp-1 receptor agonist market , including forecasts for subscribers. This country databook contains high-level insights into UK glp-1 receptor agonist market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
UK glp-1 receptor agonist market size, by product, 2018-2030 (US$M)
UK GLP-1 Receptor Agonist Market Outlook Share, 2024 & 2030 (US$M)
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
